TapImmune, Inc. to Present Progress on Clinical Trials for Cancer Vaccines

Chairman and CEO, Dr. Glynn Wilson, and COO, Dr John Bonfiglio, will speak with investors and advisors through an interactive real-time virtual conference on Thursday, February 2, 2017. During the webinar, Dr. Bonfiglio and Dr. Wilson will focus on the company’s recent accomplishments and progress, especially surrounding its sponsored Phase 2 trial in triple-negative breast cancer now…

Q&A with TapImmune CEO Dr. Glynn Wilson, on a Vaccine to Prevent Cancer Recurrence, in Multiple Phase II Trials

A vaccine that can prevent the recurrence and metastasis of cancer would save countless lives. In the past century, vaccines have virtually eradicated life threatening diseases including polio and tuberculosis. Medical science may soon be at the point of delivering a cancer vaccine. Scientists at TapImmune are working closely with leading institutions and a big…

Join TapImmune at Jacksonville’s Immunotherapy Development Program

BioFlorida-Event-April-19-2016 UPCOMING EVENT Jacksonville’s Immunotherapy Development Program The BioFlorida Northeast Chapter – Jacksonville has put together a program at Mayo Clinic focusing on the partnership between the clinic and TapImmune. Join to hear A Clinical Trial Story where representatives both from Mayo Clinic and TapImmune share their journey to date. Mayo will discuss their immunotherapy…

StockNewsNow.com Publishes New SNNLive Video Interview With TapImmune, Inc.

https://tapimmune.com/wp-content/uploads/2016/03/New_SNN_logo.jpg LOS ANGELES, CA–(Posted on Marketwired – March 17, 2016) – StockNewsNow.com, The Official MicroCap News Source™, today published an SNNLive Video Interview with Glynn Wilson, Ph.D., Chairman & CEO of TapImmune, Inc. (OTCQB: TPIV), an immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease, according…